Binding of pixantrone to DNA at CpA dinucleotide sequences and bulge structures.

The binding of the anti-cancer drug pixantrone to three oligonucleotide sequences, d(TCATATGA)2, d(CCGAGAATTCCGG)2 {double bulge = DB} and the non-self complementary d(TACGATGAGTA) : d(TACCATCGTA) {single bulge = SB}, has been studied by NMR spectroscopy and molecular modelling. The upfield shifts observed for the aromatic resonances of pixantrone upon addition of the drug to each oligonucleotide confirmed the drug bound by intercalation. For the duplex sequence d(TCATATGA)2, NOEs were observed from the pixantrone aromatic H7/8 and aliphatic Ha/Hb protons to the H6/H8 and H1' protons of the C2, A3, T6 and G7 nucleotides, demonstrating that pixantrone preferentially binds at the symmetric CpA sites. However, weaker NOEs observed to various protons from the T4 and A5 residues indicated alternative minor binding sites. NOEs from the H7/H8 and Ha/Hb protons to both major (H6/H8) and minor groove (H1') protons indicated approximately equal proportions of intercalation was from the major and minor groove at the CpA sites. Intermolecular NOEs were observed between the H7/H8 and H4 protons of pixantrone and the A4H1' and G3H1' protons of the oligonucleotide that contains two symmetrically related bulge sites (DB), indicative of binding at the adenine bulge sites. For the oligonucleotide that only contains a single bulge site (SB), NOEs were observed from pixantrone protons to the SB G7H1', A8H1' and G9H1' protons, confirming that the drug bound selectively at the adenine bulge site. A molecular model of pixantrone-bound SB could be constructed with the drug bound from the minor groove at the A8pG9 site that was consistent with the observed NMR data. The results demonstrate that pixantrone preferentially intercalates at adenine bulge sites, compared to duplex DNA, and predominantly from the minor groove.

[1]  B. Coiffier,et al.  Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. , 2012, The Lancet. Oncology.

[2]  J. Collins,et al.  DNA binding by pixantrone. , 2010, Organic & biomolecular chemistry.

[3]  G. Pezzoni,et al.  CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity , 2009, Nucleic acids research.

[4]  J. Collins,et al.  Metal complexes as structure-selective binding agents for nucleic acids , 2009 .

[5]  G. Varani,et al.  Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone). , 2009, Chemistry & biology.

[6]  J. Barton,et al.  DNA mismatch binding and antiproliferative activity of rhodium metalloinsertors. , 2009, Journal of the American Chemical Society.

[7]  J. Barton,et al.  Recognition of abasic sites and single base bulges in DNA by a metalloinsertor. , 2009, Biochemistry.

[8]  G. Pezzoni,et al.  Formaldehyde-Activated Pixantrone Is a Monofunctional DNA Alkylator That Binds Selectively to CpG and CpA Doublets , 2008, Molecular Pharmacology.

[9]  J. Barton,et al.  Metallo-intercalators and metallo-insertors. , 2007, Chemical communications.

[10]  S. Cutts,et al.  Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent , 2007, Nucleic acids research.

[11]  M. Searle,et al.  Structure of a drug-induced DNA T-bulge: implications for DNA frameshift mutations. , 2002, Angewandte Chemie.

[12]  T. Kunkel,et al.  Indirect readout of DNA sequence at the primary-kink site in the CAP-DNA complex: alteration of DNA binding specificity through alteration of DNA kinking. , 2001, Journal of molecular biology.

[13]  C. Manzotti,et al.  Bbr 2778, an Aza-anthracenedione Endowed with Preclinical Anticancer Activity and Lack of Delayed Cardiotoxicity , 2001, Tumori.

[14]  J. Smyth,et al.  A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. , 2000, European journal of cancer.

[15]  A. Travers,et al.  The acidic tail of the high mobility group protein HMG-D modulates the structural selectivity of DNA binding. , 1997, Journal of molecular biology.

[16]  J. Cáceres-Cortés,et al.  Binding of the antitumor drug nogalamycin to bulged DNA structures. , 1996, Biochemistry.

[17]  M. Hacker,et al.  Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. , 1995, Biochemical pharmacology.

[18]  D. Lilley.  Kinking of DNA and RNA by base bulges. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Capranico,et al.  Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. , 1995, Molecular pharmacology.

[20]  M. Hacker,et al.  Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. , 1995, Cancer letters.

[21]  R. Wartell,et al.  Influence of neighboring base pairs on the stability of single base bulges and base pairs in a DNA fragment. , 1995, Biochemistry.

[22]  D. Patel,et al.  Conformation of adenosine bulge-containing deoxytridecanucleotide duplexes in solution. Extra adenosine stacks into duplex independent of flanking sequence and temperature. , 1989, The Journal of biological chemistry.

[23]  A. Sartorelli,et al.  The structural basis for anthracycline antibiotic stimulation of oxygen consumption by HL-60 cells and mitochondria. , 1987, Cancer biochemistry biophysics.

[24]  D. Patel,et al.  Sequence-dependent conformation of DNA duplexes. The AATT segment of the d(G-G-A-A-T-T-C-C) duplex in aqueous solution. , 1986, The Journal of biological chemistry.

[25]  I. Tinoco,et al.  Ethidium ion binds more strongly to a DNA double helix with a bulged cytosine than to a regular double helix. , 1985, Biochemistry.

[26]  R. Kaptein,et al.  Sequential resonance assignments in 1H NMR spectra of oligonucleotides by two-dimensional NMR spectroscopy. , 1984, Biochemistry.

[27]  J. Feigon,et al.  Two-dimensional proton nuclear magnetic resonance investigation of the synthetic deoxyribonucleic acid decamer d(ATATCGATAT)2. , 1983, Biochemistry.

[28]  C. Gisselbrecht,et al.  Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. , 2003, Haematologica.

[29]  R. M. Wadkins.  Targeting DNA secondary structures. , 2000, Current Medicinal Chemistry.